BioWorld

Aprea’s WEE1 inhibitor set to enter phase I for cyclin E-overexpressing cancers

Aprea’s WEE1 inhibitor set to enter phase I for cyclin E-overexpressing cancers March 12, 2024 ...
Nasdaq

Zentalis Doses First Patient In Phase 2 DENALI Trial Of Azenosertib In Cyclin E1+ PROC

(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), Monday announced the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial evaluating azenosertib in Cyclin E1+ ...
Business Wire

Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
ascopubs.org

Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: Phase ...

AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following ...
BioWorld

Aprea’s WEE1 inhibitor set to enter phase I for cyclin E-overexpressing cancers

Home » Aprea’s WEE1 inhibitor set to enter phase I for cyclin E-overexpressing cancers To read the full story, subscribe or sign in. Cancer ...